Breyanzi’s Reimbursement in Japan Matched to Kymriah’s and Yescarta’s
On Wednesday, May 19, Japan’s Ministry of Health, Labor, and Welfare (MHLW) listed Breyanzi (BMS) in the NHI’s reimbursement price list (publication, Nichiyaku, May 2021). Below, Celltelligence provides thoughts on Breyanzi’s lower price in Japan while discussing the potential impact on pricing for upcoming cell therapies.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.